Company Snapshot

Investment Thesis

Biogen focuses on neurology with durable multiple sclerosis cash flows and new launches in Alzheimer's and rare disease. Pipeline optionality and cost discipline support a return to growth.

  • MS Foundation: Tecfidera, Vumerity, and Tysabri fund R&D and BD.
  • Alzheimer's Catalyst: Leqembi rollout with Eisai opens blockbuster potential.
  • Pipeline Depth: ALS, depression, ophthalmology, and biosimilars diversify revenue.

Strategic Mix

Multiple Sclerosis Oral and infusible therapies
Spinal Muscular Atrophy Spinraza franchise
Biosimilars Anti-TNF portfolio in Europe and U.S.
Emerging Neuro Leqembi, Qalsody, zuranolone, gene therapy programs

Mix reflects Biogen's therapeutic franchises as disclosed in filings.

Recent Performance

MTD TBD
QTD TBD
YTD TBD
5Y TBD

Maxim is cueing up returns data for this security. Once the nightly supported.csv job runs, these metrics will auto-populate.

Strategic Insights

Leqembi Access

Broadening infusion centers and reimbursement crucial for uptake.

Cost Reset

Productivity program frees cash for growth deals.

Partner Model

Shared economics with Eisai, Sage, and others manages risk.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...